• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • GPs

Gimv launches life sciences investment platform

Gimv launches life sciences investment platform
Bram Vanparys, Gimv
  • Rachel Lewis
  • 15 June 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Listed investor Gimv is carving out its life sciences portfolio into a new platform that will give it the firepower to deploy bigger tickets and increase the size of its portfolio, the firm tells Unquote.

The new strategy will be supported by a dedicated team and allow for a more VC-style deployment and access to new capital, distinct from its buyout pool. The move comes as closed-ended funds are increasing investment in the sector.

"Over the last few years we've wanted to do bigger tickets as venture capital rounds are increasing," said managing partner Bram Vanparys, who will be leading the new platform. "We've always had the mindset to be lead or co-lead and as rounds get larger the tickets get bigger."

Gimv will now look to deploy tickets of EUR 10m-EUR 15m in Series A or B companies, reserving a similar amount for follow-ons. Earlier, it could invest a maximum of EUR 10m per ticket.

The investor is also spinning out its current 12 portfolio companies into the new platform and will seek to grow it to a total of 20 in the coming two to three years.

Like all of its current investments, it will deploy a few hundred million euros from its balance sheet instead of raising new structured funds. It will also not be taking on any external equity investors into the firm, bucking the trend recently followed by specialist life science investors Sofinnova Partners, Abingworth, and LSP, who have all seen investment from large-cap private equity firms in the past half-year.

The increased attention to life sciences from VC and PE funds comes as companies are finding it more difficult to raise cash in the public markets. "Now is the right time for us to more ambitiously invest," said Vanparys.

"Valuation expectations haven't worked on exciting opportunities in the past but now the parameters should move where there's more flexibility. We don't see any issue deploying cash, moving forward."

As macro effects trickle down to private markets, some investors may take more time to raise funds, which creates opportunities for Gimv as an evergreen investor, he added.

Specialist VCs including Forbion and Cathay have recently raised funds to plug the capital markets gap, with healthcare specialist funds already on track for a record-breaking year.

Investments
Gimv is mostly interested in drug development companies at the early pre-clinical stage, or with significant clinical data. It can do crossover investments as well as PIPE but sees these as more opportunistic, he added.

Around 90% of its investments are in therapeutic areas like small molecules, antibodies, gene therapy, and cell therapy with the balance in medtech, digital health and agrotech, depending on where the team has expertise.

The firm's investment structure means it is not bound to holding periods, but it does tend to follow the typical 4-7 year holding period, especially where it syndicates on the equity.
Gimv's current life sciences team has seven people, all with a science background, and will expand as the portfolio grows.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • GPs
  • Healthcare
  • Benelux
  • Gimv

More on GPs

IPO offers CVC chance to become multi-asset consolidator
IPO offers CVC chance to become multi-asset consolidator

Potential IPO also offers monetisation solution for founders and GP stakes investor Blue Owl

  • GPs
  • 25 August 2023
VC Profile: Possible Ventures lines up frontier tech deals halfway through fresh EUR 60m fundraise
VC Profile: Possible Ventures lines up frontier tech deals halfway through fresh EUR 60m fundraise

Germany-based pre-seed investor is set to hold a first close for its third fund in mid-September

  • GPs
  • 25 August 2023
GP Profile: Apheon builds on family roots, mulls exits and reinvestment opportunities
GP Profile: Apheon builds on family roots, mulls exits and reinvestment opportunities

Belgian GP, formerly known as Ergon, to continue to target family- and entrepreneur-owned European businesses

  • GPs
  • 18 August 2023
Kudu to step up boutique GP stake deals in Europe
Kudu to step up boutique GP stake deals in Europe

MassMutual-backed investor aims to add more infrastructure and specialised equity GPs to its portfolio

  • GPs
  • 09 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013